Related Experiment Video
Updated: Feb 6, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study
Yossi Taieb1,2, Sharon Baum1,2, Dan Ben Amitai2,3
1a Dermatology Department , Sheba Medical Center , Ramat Gan , Israel.
Insights
Methotrexate effectively treats severe childhood atopic dermatitis. Over half of pediatric patients showed improvement, with significant score reductions and good tolerability, making it a viable option for refractory cases.
Area of Science:
- Dermatology
- Pediatric Medicine
- Pharmacology
Background:
- Atopic dermatitis is a chronic inflammatory skin condition.
- Methotrexate is an off-label systemic treatment for severe atopic dermatitis.
- Pediatric patients with uncontrolled atopic dermatitis often require systemic therapy.
Purpose of the Study:
- To evaluate the safety and efficacy of methotrexate in children with atopic dermatitis.
- To assess treatment outcomes in pediatric patients with refractory atopic dermatitis.
Main Methods:
- Multicenter, retrospective study design.
- Review of medical records for 26 pediatric patients.
- Analysis of Investigator Global Assessment (IGA) scores before and after methotrexate treatment.
Main Results:
- 53.85% of patients experienced clinical improvement at 3 and 6 months.
- Significant reduction in IGA scores observed at 3 and 6 months post-treatment.
- High tolerability with only one patient discontinuing treatment due to adverse events (10.35%).
- Median patient satisfaction rate of 7.5/10.
Conclusions:
- Methotrexate is a tolerable and effective treatment for refractory childhood atopic dermatitis.
- The study supports the use of methotrexate in pediatric patients with severe atopic dermatitis.
- Further research may explore long-term outcomes and optimal dosing.
Background:
Atopic dermatitis is a chronic inflammatory skin disease. Methotrexate is an off-label systemic agent for treating uncontrolled atopic dermatitis.
Objective:
This study assessed the safety and efficacy of methotrexate in pediatric patients with atopic dermatitis.
Methods:
This multicenter, retrospective study assessed pediatric patients with atopic dermatitis who were treated with methotrexate.
Results:
Medical records of 26 pediatric patients with atopic dermatitis were reviewed. All the patients had Investigator Global Assessment (IGA) scores of 3-4 and had received systemic therapy before receiving methotrexate. In all, 53.85% patients showed clinical improvement at 3 and 6 months after methotrexate initiation. The IGA scores of the patients decreased significantly at 3 months after methotrexate initiation compared with those at baseline; moreover, the IGA scores of the patients at 6 months after methotrexate initiation were lower than those at 3 months after methotrexate initiation. In all, 54% study patients are still undergoing methotrexate treatment. Median satisfaction rate with methotrexate was 7.5/10. However, 10.35% patients developed adverse events, of which only one patient discontinued the treatment.
Conclusions:
Our results indicate that methotrexate is a tolerable and effective agent for treating refractory childhood atopic dermatitis.
More Related Videos
Related Concept Videos
Erikson's Theory on Socioemotional Development during Childhood
The first four of Erikson's eight...
Piaget's Theory of Cognitive Development from Childhood into Adulthood
Schemata: Building Blocks of Knowledge
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Case Studies
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Longitudinal Studies

